| US 7,553,992 B2 | ||
| Modified release formulations of a bupropion salt | ||
| Werner Oberegger, Mississauga (Canada); Paul Maes, Toronto (Canada); Stefano Turchetta, Rome (Italy); Pietro Massardo, Rome (Italy); and Mohammad Ashty Saleh, Oakville (Canada) | ||
| Assigned to Biovail Laboratories International S.R.L., St. Michael (Barbados) | ||
| Filed on May 31, 2007, as Appl. No. 11/755,946. | ||
| Application 11/755946 is a continuation of application No. 11/475252, filed on Jun. 27, 2006, granted, now 7,241,805. | ||
| Claims priority of provisional application 60/693906, filed on Jun. 27, 2005. | ||
| Prior Publication US 2008/0051606 A1, Feb. 28, 2008 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C07C 225/10 (2006.01) | ||
| U.S. Cl. 564—345 | 3 Claims |
1. A crystalline compound of the formula:
 having the powder X-ray diffraction pattern shown in FIG. 54.
|